AU2002243920A1 - Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same - Google Patents

Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same

Info

Publication number
AU2002243920A1
AU2002243920A1 AU2002243920A AU2002243920A AU2002243920A1 AU 2002243920 A1 AU2002243920 A1 AU 2002243920A1 AU 2002243920 A AU2002243920 A AU 2002243920A AU 2002243920 A AU2002243920 A AU 2002243920A AU 2002243920 A1 AU2002243920 A1 AU 2002243920A1
Authority
AU
Australia
Prior art keywords
compounds
treat
methods
same
neuropsychiatric disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002243920A
Inventor
Linda D. Artman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire NPS Pharmaceuticals Inc
Original Assignee
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NPS Pharmaceuticals Inc filed Critical NPS Pharmaceuticals Inc
Publication of AU2002243920A1 publication Critical patent/AU2002243920A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002243920A 2001-02-08 2002-02-08 Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same Abandoned AU2002243920A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26731001P 2001-02-08 2001-02-08
US60/267,310 2001-02-08
PCT/US2002/003876 WO2002062963A2 (en) 2001-02-08 2002-02-08 Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same

Publications (1)

Publication Number Publication Date
AU2002243920A1 true AU2002243920A1 (en) 2002-08-19

Family

ID=23018239

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002243920A Abandoned AU2002243920A1 (en) 2001-02-08 2002-02-08 Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same

Country Status (4)

Country Link
EP (1) EP1385520A4 (en)
AU (1) AU2002243920A1 (en)
CA (1) CA2437353A1 (en)
WO (1) WO2002062963A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
AP2780A (en) 2006-10-18 2013-09-30 Pfizer Prod Inc Biaryl ether urea compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618955A (en) * 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
US5688825A (en) * 1996-05-31 1997-11-18 University Of Connecticut Anandamide amidase inhibitors as analgesic agents
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
US5798392C1 (en) * 1996-08-28 2002-06-04 Univ Texas Sulfonyl fluorides for the treatment of alzheimer's disease
KR100594400B1 (en) * 1996-08-30 2006-07-03 엔피에스 파마슈티칼즈, 인코포레이티드 Treatment of spasticity, convulsions by isovaleric acid derivatives cns depressants

Also Published As

Publication number Publication date
WO2002062963A2 (en) 2002-08-15
CA2437353A1 (en) 2002-08-15
EP1385520A4 (en) 2007-03-21
EP1385520A2 (en) 2004-02-04
WO2002062963A3 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
MXPA03007960A (en) Compounds and methods for the treatment of urogenital disorders.
HUP0003964A2 (en) Methods for treating thrombotic disorders
AU7085100A (en) Method for treating otic disorders
AU2001247474A1 (en) Compounds for the treatment of psychiatric or substance abuse disorders
EP1067940A4 (en) Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
IL208191A0 (en) Compositions and methods for treating rage-associated disorders
AU2001269799A1 (en) Methods for treating various eye disorders
IL159461A0 (en) Method for enhancing the effectiveness of cancer therapies
AU8298801A (en) Methods for treating atopic disorders
EP1567198A4 (en) Materials and methods for treating ocular-related disorders
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
AU2002225930A1 (en) Methods for treating phosphatide-containing mixtures
PL354110A1 (en) Combined therapy for treating the both alcoholism and alcohol dependence
EP1207874A4 (en) Methods of treating proliferative disorders
WO2003039490A9 (en) Compositions and methods for diagnosing and treating mental disorders
MXPA03006607A (en) Combined method for treating hormono-dependent disorders.
GB2389532C (en) The method of treating cancer
AU2001288792A1 (en) Method of treating neurologic disorders
AU2002304931A1 (en) Methods for treating disorders of the nervous and reproductive systems
AU2002320352A1 (en) Methods for treating or preventing sclerotic disorders using cd2-binding agents
WO2002061430A3 (en) Methods and reagents for treating autoimmune disorders
AU2002243920A1 (en) Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
CZ20011872A3 (en) Isonipecotamides for the treatment of integrin-mediated disorders
AU5855899A (en) Method for identifying substances for the treatment of c-jun-mediated disorders
AU3753500A (en) Methods of treating fibrinogen-related disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase